Abstract
New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively investigated to block VEGF and its pro-angiogenic functions. Some of these agents have been approved by FDA and some are currently in clinical trials. Combination therapies are also being pursued for better tumor control. By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process. Moreover, the imaging will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy. This review summarizes the current status of tumor therapeutic agents targeting to VEGF and the applications of VEGF related molecular imaging.
Keywords: Vascular endothelial growth factor, VEGF, targeted therapy, molecular imaging
Current Drug Targets
Title: Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Volume: 11 Issue: 8
Author(s): Gang Niu and Xiaoyuan Chen
Affiliation:
Keywords: Vascular endothelial growth factor, VEGF, targeted therapy, molecular imaging
Abstract: New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively investigated to block VEGF and its pro-angiogenic functions. Some of these agents have been approved by FDA and some are currently in clinical trials. Combination therapies are also being pursued for better tumor control. By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process. Moreover, the imaging will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy. This review summarizes the current status of tumor therapeutic agents targeting to VEGF and the applications of VEGF related molecular imaging.
Export Options
About this article
Cite this article as:
Niu Gang and Chen Xiaoyuan, Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy, Current Drug Targets 2010; 11 (8) . https://dx.doi.org/10.2174/138945010791591395
DOI https://dx.doi.org/10.2174/138945010791591395 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science Antimicrobial Activity of Willowherb (Epilobium angustifolium L.) Leaves and Flowers
Current Drug Targets Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Protein Misfolding and Misprocessing in Complex Disease
Protein & Peptide Letters The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry Monitoring of Environmental Metals in Human Blood: The Need for Data Validation
Current Analytical Chemistry Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers
Current Medicinal Chemistry Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews